Brokers Issue Forecasts for Cytokinetics Q1 Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Cytokinetics in a research note issued to investors on Friday, February 28th. HC Wainwright analyst J. Pantginis expects that the biopharmaceutical company will post earnings per share of ($1.42) for the quarter. HC Wainwright currently has a “Buy” rating and a $120.00 target price on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. HC Wainwright also issued estimates for Cytokinetics’ Q2 2025 earnings at ($1.44) EPS, Q3 2025 earnings at ($1.44) EPS, Q4 2025 earnings at ($1.53) EPS and FY2025 earnings at ($5.83) EPS.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.03. The business had revenue of $16.93 million during the quarter, compared to analyst estimates of $14.26 million.

Other equities analysts have also issued research reports about the stock. Stifel Nicolaus initiated coverage on shares of Cytokinetics in a report on Wednesday, January 22nd. They issued a “buy” rating and a $80.00 price target on the stock. Citigroup started coverage on Cytokinetics in a report on Friday, February 7th. They issued a “buy” rating and a $86.00 target price on the stock. Royal Bank of Canada lifted their price objective on Cytokinetics from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Wednesday, December 18th. Morgan Stanley raised shares of Cytokinetics from an “equal weight” rating to an “overweight” rating and dropped their target price for the stock from $70.00 to $67.00 in a research report on Thursday, February 13th. Finally, Needham & Company LLC restated a “buy” rating and issued a $72.00 price target on shares of Cytokinetics in a report on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Cytokinetics has a consensus rating of “Moderate Buy” and an average price target of $82.00.

Cytokinetics Price Performance

CYTK opened at $43.69 on Monday. Cytokinetics has a 1 year low of $40.53 and a 1 year high of $75.71. The company’s 50 day simple moving average is $47.00 and its 200 day simple moving average is $51.03. The stock has a market capitalization of $5.16 billion, a PE ratio of -8.12 and a beta of 0.83. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28.

Insider Buying and Selling at Cytokinetics

In related news, Director Wendall Wierenga sold 742 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $48.61, for a total value of $36,068.62. Following the sale, the director now directly owns 24,559 shares of the company’s stock, valued at $1,193,812.99. This represents a 2.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Fady Ibraham Malik sold 7,300 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $50.64, for a total transaction of $369,672.00. Following the transaction, the executive vice president now directly owns 116,071 shares of the company’s stock, valued at approximately $5,877,835.44. This represents a 5.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 17,822 shares of company stock valued at $874,048 in the last ninety days. Insiders own 3.40% of the company’s stock.

Hedge Funds Weigh In On Cytokinetics

Several large investors have recently modified their holdings of CYTK. International Assets Investment Management LLC acquired a new stake in Cytokinetics during the third quarter valued at approximately $558,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Cytokinetics by 24.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,256 shares of the biopharmaceutical company’s stock valued at $223,000 after acquiring an additional 833 shares in the last quarter. State of Alaska Department of Revenue raised its position in shares of Cytokinetics by 7.4% during the 3rd quarter. State of Alaska Department of Revenue now owns 13,390 shares of the biopharmaceutical company’s stock valued at $706,000 after acquiring an additional 925 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in Cytokinetics by 2.9% during the third quarter. Nisa Investment Advisors LLC now owns 15,062 shares of the biopharmaceutical company’s stock worth $795,000 after purchasing an additional 430 shares during the last quarter. Finally, New York State Teachers Retirement System increased its stake in Cytokinetics by 1.4% during the third quarter. New York State Teachers Retirement System now owns 113,800 shares of the biopharmaceutical company’s stock valued at $6,009,000 after purchasing an additional 1,600 shares during the last quarter.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.